Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06427291
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 129
- Registration Number
- NCT06423937
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
The Impact of Colorectal Cancer Screening on Surgical Outcomes
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 4000
- Registration Number
- NCT06416501
- Locations
- 🇨🇳
Xinxiang Li, Shanghai, Shanghai, China
Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT06406426
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 73
- Registration Number
- NCT06404736
- Locations
- 🇨🇳
Zhimin Shao, Shanghai, Not US/Canada, China
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 76
- Registration Number
- NCT06404463
Impact of a Mock-up Fact-checking Extension on HPV Vaccine Misinformation: A Survey Experiment
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1200
- Registration Number
- NCT06405048
- Locations
- 🇨🇳
Jiading District Center for Disease Control and Prevention, Shanghai, Shanghai, China
🇨🇳Chizhou Health Center for Disease Control and Prevention, Chizhou, Anhui, China
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 172
- Registration Number
- NCT06402708
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT06401447
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
The Study on the Mechanism of Radiotherapy-elicited Immune Response
Recruiting
- Conditions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT06393140
- Locations
- 🇨🇳
Fudan University Shanghai cancer center, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath